Financial stability appears fragile with equity plummeting to $291,000 in 2026Q1 and a debt-to-equity ratio that has spiked to 1.50, signaling significant structural vulnerability.
| Total Current Assets | 4.07M | 6.64M | 2.25M | 4.98M | 8.84M | 407.8K | 51.7K |
| Cash & Short-Term Investments | 2.41M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K | 51.7K |
| Cash Only | 2.41M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K | 51.7K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.65M | 646K | 97K | 49K | 67K | 0 | 0 |
| Total Non-Current Assets | 537K | 578K | 613K | 277K | 494K | 115.01M | 77.7K |
| Property, Plant & Equipment | 403K | 437K | 560K | 247K | 464K | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 168K | 57K | 0 | 0 | 0 | 115.01M | 0 |
| Other Non-Current Assets | 76K | 84K | 53K | 30K | 30K | 0 | 77.7K |
| Total Assets | 4.6M | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M | 129.4K |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 513.21% | 152.01% | -45.53% | -43.68% | -91.91% | 89092.47% | - |
| Total Current Liabilities | 4.06M | 2.76M | 3.52M | 2.2M | 1.61M | 348.58K | 29.4K |
| Accounts Payable | 912K | 787K | 929K | 319K | 240K | 0 | 0 |
| Days Payables Outstanding | 36.36K | - | - | - | - | - | - |
| Short-Term Debt | 185K | 182K | 1M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.91M | 1.74M | 644K | 407K | 256K | 348.58K | 29.4K |
| Current Ratio | 1.00x | 2.41x | 0.64x | 2.27x | 5.49x | 1.17x | 1.76x |
| Quick Ratio | 1.00x | 2.41x | 0.64x | 2.27x | 5.49x | 1.17x | 1.76x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 251K | 1.85M | 3.33M | 15.12M | 14.8M | 160.34K | 269.99K |
| Long-Term Debt | 251K | 286K | 2.96M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 337K | 0 | 368K | 59K | 156K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.57M | 0 | 15.06M | 14.65M | 160.34K | 269.99K |
| Total Liabilities | 4.31M | 4.61M | 6.85M | 17.31M | 16.41M | 508.92K | 299.39K |
| Total Debt | 436K | 468K | 4.49M | 171K | 271K | 0 | 0 |
| Net Debt | -1.98M | -5.52M | 3.3M | -4.42M | -7.99M | -38.94K | -51.7K |
| Debt / Equity | 1.50x | 0.18x | - | - | - | - | - |
| Debt / EBITDA | 0.04x | 0.04x | - | - | - | - | - |
| Net Debt / EBITDA | -0.19x | -0.47x | - | - | - | - | - |
| Interest Coverage | -2152.83x | -915.08x | -317.35x | -520.11x | -45.41x | - | - |
| Total Equity | 291K | 2.6M | -3.99M | -12.06M | -7.08M | 114.91M | -169.99K |
| Equity Growth % | 429.68% | 165.25% | 66.91% | -70.31% | -106.16% | 67695.3% | - |
| Book Value per Share | 0.90 | 19.58 | -6.39 | -107.91 | -4.23 | 69.62 | -0.10 |
| Total Shareholders' Equity | 291K | 2.6M | -3.99M | -15.48M | -10.66M | 114.91M | -169.99K |
| Common Stock | 46K | 42K | 2K | 1K | 1K | 115M | 298 |
| Retained Earnings | -57.9M | -55.17M | -43.25M | -26.81M | -21.87M | -951.08K | -195.86K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.42M | 3.59M | 0 | 0 |
Imminent capital depletion risk
According to recent financial statements, SLXNW's cash position declined to $2.4 million in 2026Q1 from $6.0 million in 2025Q4, leaving the company with a current ratio of 1.00 that suggests minimal flexibility to absorb unexpected clinical trial cost overruns or operational delays.
The rapid contraction in liquid assets relative to the company's historical burn rate indicates that the current liquidity buffer is insufficient for sustained operations. Investors should monitor the company's ability to secure non-dilutive funding, as the current ratio of 1.00 leaves virtually no margin for error in managing near-term liabilities.
As reported in quarterly filings, equity has plummeted to $291,000 in 2026Q1 from $2.6 million in 2025Q4, reflecting the persistent accumulation of losses that threatens to push the company back into a negative equity position similar to the 2024 fiscal year.
The volatility in equity highlights the company's reliance on external capital injections to offset recurring net losses. This trend suggests that shareholders face a high probability of further dilution, as the current equity base provides little cushion against the ongoing depletion of retained earnings.
Based on the provided balance sheet data, the company's total assets have contracted from $11.6 million in 2025Q3 to $4.6 million in 2026Q1, signaling a deteriorating financial trajectory that underscores the firm's precarious position as a pre-revenue clinical-stage entity.
The consistent decline in total assets over the last three quarters suggests that the company is consuming its resource base faster than it can replenish it through financing. This trajectory warrants caution, as it implies that the business model is currently unsustainable without frequent and potentially dilutive capital market interventions.
As disclosed in recent filings, the company's debt-to-equity ratio spiked to 1.50 in 2026Q1, which, when viewed alongside the $57.9 million in accumulated losses, suggests that the firm's minimal debt load masks a deeper structural reliance on equity-based financing to survive.
While the absolute debt level appears manageable, the high D/E ratio is a function of a shrinking equity base rather than strategic leverage. This distortion suggests that the company's financial health is more vulnerable than headline debt figures might imply, as there is little room for further balance sheet degradation.
Quick answers to the most common questions about buying SLXNW stock.
As of 2025, Silexion Therapeutics Ltd. (SLXNW) had total assets of $7.2M including $6.6M in current assets.
Silexion Therapeutics Ltd. (SLXNW) carries total debt of $0.5M, offset by $6.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Silexion Therapeutics Ltd. (SLXNW) has total shareholders' equity (book value) of $2.6M ($19.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Silexion Therapeutics Ltd. (SLXNW) reported a current ratio of 2.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.